Skip to main content
IMRN
NASDAQ Life Sciences

Shareholders Approve Highly Dilutive Share Issuance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.726
Mkt Cap
$6.98M
52W Low
$0.677
52W High
$2.39
52W Position info
7.3% above low
Off High info
70% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

IMRN is trading near its 52-week low of $0.677 (7.3% above the low) on light trading volume (0.1× avg).

Summary

Immuron Ltd shareholders have approved the prior issuance of 55.1 million shares, which represents over 55% dilution, solidifying a significant capital event.


Key Events · Financing and Capital Events · IMRN

  • Shareholder Ratification Approved

    Shareholders passed all resolutions at the Extraordinary General Meeting, including the ratification of a prior issuance of 55.1 million shares.

  • Significant Dilution Confirmed

    The approved share issuance represents over 55% dilution to existing shareholders, finalizing a major capital event for the company.

  • Follows Prior Disclosure

    This approval follows the company's January 12, 2026 filing, which announced the intent to seek ratification for the dilutive share issuance.


Analysis · IMRN · Life Sciences

This 6-K filing confirms that Immuron Ltd shareholders have formally ratified the previously announced issuance of 55.1 million shares. This approval finalizes a highly dilutive capital event, representing over 55% dilution to existing shareholders. The ratification follows the company's announcement on January 12, 2026, of its intent to seek shareholder approval for this significant share issuance. While the intent to dilute was previously disclosed, the formal approval removes any uncertainty regarding the execution of this substantial capital raise.

How filings like this one have moved

In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMRN was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7M. The 52-week trading range was $0.68 to $2.39. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMRN - Latest Insights

IMRN
Aug 28, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $1.38 info
Change: +$0.220 (+19%) info
Market Cap: $12.034M info
IMRN
Jul 27, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.11
Real-time Price: $1.38 info
Change: +$0.2726 (+25%) info
Market Cap: $12.034M info
IMRN
Jul 20, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.26
Real-time Price: $1.38 info
Change: +$0.120 (+10%) info
Market Cap: $12.034M info
IMRN
Jul 16, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.19
Real-time Price: $1.38 info
Change: +$0.190 (+16%) info
Market Cap: $12.034M info
IMRN
Jul 06, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.10
Real-time Price: $1.38 info
Change: +$0.280 (+25%) info
Market Cap: $12.034M info